Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 9/20 | 0.41 |
| ▸ | PARP11 | Q9NR21 | 8/20 | 0.41 |
| ▸ | PARP1 | P09874 | 6/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.34 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.34 |
| ▸ | F7 | P08709 | 1/20 | 0.34 |
| ▸ | F3 | P13726 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30330221 | 0.78 | GPR52 (0.36) | PARP10PARP11PARP1PDPK1GPR52 | |
| SCHEMBL3601682 | 0.77 | ELANE (0.44) | AURKAGRM5 | |
| SCHEMBL30329606 | 0.73 | CDC7 (0.38) | PARP10PARP11PARP1PDPK1GPR52 | |
| SCHEMBL17256724 | 0.69 | GPR52 (0.42) | PARP10PARP11PARP1PDPK1GPR52 | |
| SCHEMBL10142387 | 0.69 | ELANE (0.36) | AURKA | |
| SCHEMBL21987940 | 0.69 | PKN1 (0.40) | PARP10PARP11PARP1PDPK1GPR52 | |
| SCHEMBL3606986 | 0.69 | HPGD (0.39) | AURKA | |
| SCHEMBL3606988 | 0.69 | HPGD (0.39) | AURKA | |
| SCHEMBL21483767 | 0.66 | GPR52 (0.40) | PARP10PARP11PARP1PDPK1GPR52 | |
| SCHEMBL21483766 | 0.66 | JAK2 (0.41) | PARP10PARP11PARP1PDPK1GPR52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112424195-B | Fused lactam derivatives | 住友制药株式会社 | 2025-03-25 | — | — | CN | disclosed |
| US-20250084090-A1 | SUBSTITUTED LACTAMS SHOWING SEROTONIN 5-HT RECEPTOR ACTIVITY | Sumitomo Pharma Co., Ltd. (JP) | 2025-03-13 | — | — | US | disclosed |
| US-12180213-B2 | Substituted pyrazoles showing serotonin 5-HT receptor activity | SUMITOMO PHARMA CO. LTD. (JP) | 2024-12-31 | — | — | US | disclosed |
| US-20230008875-A1 | SUBSTITUTED LACTAMS SHOWING SEROTONIN 5-HT RECEPTOR ACTIVITY | Sumitomo Pharma Co., Ltd. (JP) | 2023-01-12 | — | — | US | disclosed |
| US-20230008875-A1 | SUBSTITUTED LACTAMS SHOWING SEROTONIN 5-HT RECEPTOR ACTIVITY | Sumitomo Pharma Co., Ltd. (JP) | 2023-01-12 | — | — | US | disclosed |
| US-11466007-B2 | Substituted lactams showing serotonin 5-HT receptor activity | Sumitomo Pharma Co., Ltd. (JP) | 2022-10-11 | — | — | US | disclosed |
| EP-3828182-A1 | FUSED RING LACTAM DERIVATIVES | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2021-06-02 | — | — | EP | disclosed |
| CN-112424195-A | Condensed lactam derivatives | 大日本住友制药株式会社 | 2021-02-26 | — | — | CN | disclosed |
| US-10745401-B2 | Condensed lactam derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-08-18 | — | — | US | disclosed |
| US-10745401-B2 | Condensed lactam derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-08-18 | — | — | US | disclosed |
| US-20200255432-A1 | CONDENSED LACTAM DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-08-13 | — | — | US | disclosed |
| US-20200255432-A1 | CONDENSED LACTAM DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-08-13 | — | — | US | disclosed |
| US-20200172543-A1 | CONDENSED LACTAM DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-06-04 | — | — | US | disclosed |
| US-20200172543-A1 | CONDENSED LACTAM DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255432-A1 | CONDENSED LACTAM DERIVATIVE | PSEN1, GRIN1, HDAC1 | PARP10 2117/4885PARP11 1733/4885PARP1 1569/4885 |
| US-20250084090-A1 | SUBSTITUTED LACTAMS SHOWING SEROTONIN 5-HT RECEPTOR ACTIVITY | HTR1A, HTR5A, TPH1 | PARP10 1488/4885PARP11 1137/4885PARP1 1831/4885 |
| US-12180213-B2 | Substituted pyrazoles showing serotonin 5-HT receptor activity | HTR5A, HTR1A, TPH1 | PARP10 1864/4885PARP11 1063/4885PARP1 2201/4885 |
| US-10745401-B2 | Condensed lactam derivative | PSEN1, GRIN1, HDAC1 | PARP10 2117/4885PARP11 1733/4885PARP1 1569/4885 |
| US-11466007-B2 | Substituted lactams showing serotonin 5-HT receptor activity | HTR1A, HTR5A, TPH1 | PARP10 1488/4885PARP11 1137/4885PARP1 1831/4885 |
| US-20230008875-A1 | SUBSTITUTED LACTAMS SHOWING SEROTONIN 5-HT RECEPTOR ACTIVITY | HTR1A, HTR5A, TPH1 | PARP10 1488/4885PARP11 1137/4885PARP1 1831/4885 |
| US-20200172543-A1 | CONDENSED LACTAM DERIVATIVE | PSEN1, GRIN1, HDAC1 | PARP10 2117/4885PARP11 1733/4885PARP1 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.